Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11912104 | 0.83 | MAPT (0.41) | MMEPIK3CDNPC1ALDH1A1GAA | |
| SCHEMBL13802677 | 0.83 | MAPT (0.41) | MMEPIK3CDNPC1ALDH1A1GAA | |
| SCHEMBL13082776 | 0.76 | MME (0.31) | MMEPIK3CD | |
| SCHEMBL14360752 | 0.76 | NPC1 (0.32) | MMEPIK3CDNPC1ALDH1A1GAA | |
| SCHEMBL9891112 | 0.76 | NPC1 (0.35) | MMEPIK3CDNPC1ALDH1A1GAA | |
| SCHEMBL2931296 | 0.75 | MME (0.43) | MMEPIK3CDMAPT | |
| SCHEMBL15040816 | 0.75 | MME (0.43) | MMEPIK3CDMAPT | |
| SCHEMBL13544349 | 0.75 | KMT2A (0.45) | MMEGAAMAPTSMN1; SMN2 | |
| SCHEMBL13178384 | 0.75 | MME (0.43) | MMEPIK3CDMAPT | |
| SCHEMBL13558663 | 0.75 | MAPT (0.34) | MMEPIK3CDNPC1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190209702-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209702-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | SERPINA6, NR3C1, NR3C2 | MME 1994/4885PIK3CD 4103/4885NPC1 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.